MiR-429 Liposome Nanoparticles Inhibit Lung Cancer via Targeting of Hippo/YAP in Lung Cancer Mice

Abstract

The increasing incidence of lung cancer seriously threatens the safety of human life and property. At present, it is difficult for relevant drugs in clinical treatment to accurately identify and act on cancer cells. Therefore, liposome nanoparticles are used to carry related drugs and genes for targeted therapy, which is of great significance. Hippo/YAP signaling is related to the proliferation and apoptosis of cancer cells. Therefore, in this study, the mechanism of lung cancer cells inhibition was further analyzed by constructing miR-429 liposome nanoparticles. miR-429 liposome nanoparticles were prepared and characterized and then injected into experimental group mice after successful modeling and divided into model group, miR-429 lipid nanoparticle group, Hippo/YAP inhibitor (TDI-011536) group, and Hippo/YAP activator (XMU-MP-1) group. Lung cancer cells were taken to construct miR-429 gene silencing and miR-429 gene overexpression groups, followed by analysis of cell proliferation and levels of miR-429, Hippo and YAP. The miR-429 liposome nanoparticles promote the occurrence and development of lung cancer. The miR-429 has a certain inhibitory effect on Hippo/YAP signaling, where it reduces Hippo/YAP signaling activity and inhibits the growth of lung cancer cells. The miR-429 liposome nanoparticles can inhibit Hippo/YAP signaling, reduce their expression, thereby inhibiting lung cancer cell growth and inducing apoptosis, so miR-429 liposome nanoparticles might be used in treating lung cancer.